Psychiatric NP Scope of Practice for General Psychiatry in Georgia

You’ve built a solid psychiatric practice, but here’s the question keeping many providers up at night in 2026: Can I still prescribe Adderall, benzos, and other controlled substances via telehealth — or is the DEA about to pull the rug out?

If you’ve been following the regulatory ping-pong since COVID, you know the answer keeps changing. The good news: as of February 2026, you can still prescribe controlled substances via telehealth without an in-person exam — the DEA and HHS just extended the temporary flexibilities through December 31, 2026. The less-good news: permanent rules are coming, and they’ll reshape how telepsychiatry works.

Let’s cut through the confusion. Whether you’re a psychiatrist, PMHNP, or prescriber considering telehealth — or already doing it — here’s what you need to know about prescribing regulations right now, what’s changing, and how to stay compliant while growing your practice.

Federal Rules: What You Can Do Today (Through End of 2026)

The Current Reality

Right now, psychiatrists and psychiatric nurse practitioners can prescribe Schedule II–V controlled substances via telehealth without any prior in-person visit, thanks to the fourth extension of COVID-era flexibilities announced January 2, 2026. This applies to:

• Schedule II stimulants (Adderall, Ritalin, Vyvanse for ADHD)
• Schedule III drugs (Suboxone/buprenorphine combinations)
• Schedule IV medications (benzodiazepines like Xanax, Ativan; sleep aids like Ambien)
• Schedule V (cough suppressants with codeine, pregabalin)

The key requirements are straightforward:

• Conduct a real-time audio-visual evaluation (not just a phone call or questionnaire) to establish a legitimate patient-provider relationship
• Document the encounter thoroughly — history, mental status exam, diagnostic impression, treatment plan
• Follow your usual standard of care (you wouldn’t prescribe stimulants after a 10-minute video chat any more than you would in person)
• Use e-prescribing for controlled substances (required in most states anyway)
• Check your state’s PDMP (Prescription Drug Monitoring Program) before prescribing — mandatory in nearly every state
• Ensure you’re licensed and DEA-registered in the state where the patient is located

This extension prevents any gap in care while the DEA finalizes permanent telemedicine rules. Translation: If you’ve been doing telepsychiatry since 2020, nothing changes operationally through the end of this year.

The Ryan Haight Act Exception

Under normal circumstances, the Ryan Haight Act (2008 federal law) requires at least one in-person medical evaluation before prescribing controlled substances online. The COVID public health emergency suspended this requirement, and these extensions keep that suspension in place.

However, there’s a crucial nuance many providers miss: If a patient has ever been seen in person by any healthcare provider, you can prescribe controlled substances via telehealth with no additional restrictions. The in-person requirement is already satisfied. This matters for patients who switch to telehealth after previously seeing someone face-to-face, or who had a physical exam at urgent care, their PCP, etc.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Changing: The DEA’s Proposed Permanent Rules

The DEA isn’t extending temporary rules forever. In January 2025, they announced three proposed permanent regulations designed to balance access with safety. Here’s what psychiatrists need to know:

1. Special Telemedicine Registration for Schedule II Prescribing

The most significant proposal: a new Special Telemedicine Registration that would allow qualified providers to prescribe controlled substances to new patients via telehealth indefinitely, without ever requiring an in-person visit.

For Schedule III–V medications, any DEA-registered provider could apply for this special registration. For Schedule II drugs (stimulants, some opioids), the DEA is initially limiting eligibility to specific specialties — and psychiatrists are explicitly included in that group.

What this means practically: A board-certified psychiatrist could obtain this special registration and continue prescribing Adderall for ADHD, Ritalin for focus issues, or other Schedule II psychiatric medications via pure telehealth indefinitely. No in-person requirement, ever.

The catch: We don’t yet know the exact requirements for this registration. The DEA is still taking public comment on details like:

• Will you need to be in the same state as the patient?
• What documentation or oversight will be required?
• Will there be limits on prescription quantities or durations?
• What’s the registration fee and renewal process?

Also under this rule, online telehealth platforms (like Klarity Health and others) would be required to register with the DEA for the first time and integrate with a proposed national PDMP system. This aims to hold platforms accountable and prevent the over-prescribing scandals that made headlines in 2022–2023.

2. Expanded Buprenorphine Access (OUD Treatment)

For addiction psychiatry: The DEA proposes allowing clinicians to prescribe buprenorphine for opioid use disorder via telehealth (including audio-only) for up to 6 months before an in-person visit is required.

This is more permissive than current law would suggest. After 180 days of telehealth treatment, patients would need an in-person evaluation to continue. This recognizes that medication-assisted treatment via telehealth has dramatically improved access to OUD care.

Since the X-waiver was eliminated in 2023, any psychiatrist with a DEA license can prescribe buprenorphine without special registration. Combined with this new rule, telepsychiatry for substance use disorders would have a clear regulatory pathway.

3. VA Continuity of Care

A third rule creates special arrangements for the VA system (if a patient has been seen in person anywhere in the VA, any VA telehealth provider can prescribe controlled substances to them). Less relevant for private practice, but it signals the direction: establishing that once any in-person exam has occurred, ongoing telehealth is fully legitimate.

Timeline: These are proposed rules, not final. The DEA is accepting public comment and will likely finalize them sometime in 2026. Once final, there will be an implementation period. Expect the special telemedicine registration process to go live late 2026 or early 2027.

State-Specific Rules: Where It Gets Complicated

Federal DEA rules set the floor, but states can impose stricter requirements — and they do. Your ability to prescribe via telehealth depends heavily on where your patient is located. Here’s the breakdown for key states:

California: Telehealth-Friendly, But Check CURES

California allows telepsychiatry without in-person requirements as long as you follow the standard of care. No special state restrictions on controlled substance prescribing via telehealth.

State-specific requirements:

• Mandatory CURES PDMP check before prescribing any Schedule II–IV controlled substance for the first time, then every 4 months for ongoing prescriptions
• 100% e-prescribing (mandatory since 2022)
• Audio-only telehealth is permitted for follow-ups with established patients, but initial controlled substance prescriptions should use video

Scope note: California is phasing in full practice authority for experienced PMHNPs (2023–2026). By 2026, a PMHNP with sufficient experience can practice and prescribe independently without physician oversight.

Texas: Physician-Friendly, But NP Restrictions Are Brutal

Texas recognizes telehealth relationships and allows video evaluations to establish care. Controlled substance prescribing via telehealth is permitted under the current DEA extension.

Major restrictions:

• NPs and PAs cannot prescribe Schedule II medications (stimulants, some opioids) outside of hospital or hospice settings. Period. If you’re a PMHNP in Texas seeing ADHD patients via telehealth, you cannot prescribe Adderall — a supervising physician must write those prescriptions
• Chronic pain prescriptions: State law prohibits prescribing controlled substances for chronic pain via telemedicine without a prior in-person visit (not typically relevant to psychiatry, but know the line)
• Mandatory PDMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol

Reality check: If you’re a telepsychiatry platform operating in Texas, you need MDs on staff for any Schedule II prescribing. NPs can handle most psychiatric medications (SSRIs, mood stabilizers, some benzos), but not stimulants.

Florida: Psychiatric Exception Saves the Day

Florida has the most complex telehealth law, but it includes a crucial carve-out for psychiatry.

The rule: Schedule II controlled substances cannot be prescribed via telehealth in Florida except for:

1. Psychiatric disorder treatment
2. Inpatient hospital care
3. Hospice care
4. Nursing home residents

Translation: You can prescribe Adderall for ADHD via telehealth in Florida because ADHD is a psychiatric condition. You cannot prescribe oxycodone for back pain via telehealth (not a psychiatric indication).

Other Florida requirements:

• Must be Florida-licensed OR register as an out-of-state telehealth provider (a unique Florida option)
• Check the E-FORCSE PDMP before prescribing any controlled substance
• Schedules III–V can be prescribed via telehealth without the psychiatric restriction
• PMHNPs must have a supervising physician — Florida doesn’t allow independent practice for psychiatric nurse practitioners

Pro tip: Document the psychiatric indication clearly in every chart note. ‘Adderall 20mg for ADHD, combined type’ — not just ‘Adderall prescribed.’

New York: Clean and Simple (With Mandatory Checks)

New York embraces telehealth without state-level restrictions beyond federal law. Psychiatric prescribing via telehealth is straightforward.

Requirements:

• Mandatory I-STOP PMP check before prescribing every Schedule II, III, or IV controlled substance (among the strictest PDMP laws in the country)
• 100% e-prescribing for all prescriptions since 2016
• Experienced PMHNPs (3,600+ hours) can practice independently — no physician oversight needed

New York is not in the Interstate Medical Licensure Compact yet, so out-of-state providers need a full New York license (time-consuming but doable).

Pennsylvania: Follow Standard of Care (But Watch Collaboration Rules)

Pennsylvania doesn’t have a comprehensive telehealth statute, but the medical board permits it. No state law prohibits controlled substance prescribing via telehealth.

Key points:

• Mandatory PDMP check before prescribing opioids or benzodiazepines
• PMHNPs need collaborative agreements with at least one (ideally two) physicians to prescribe. Schedule II prescriptions limited to 30-day supplies; Schedule III–IV to 90 days
• E-prescribing required for controlled substances since 2019

Illinois: Full Practice for Experienced NPs

Illinois permits telehealth prescribing with standard-of-care requirements. No special state restrictions.

Scope advantage:

• PMHNPs can obtain Full Practice Authority after 4,000 clinical hours and additional training — then prescribe independently including controlled substances
• Even FPA NPs face one quirk: must have a physician consultation arrangement for ongoing benzodiazepines and Schedule II opioids (30-day limit without consult)
• Mandatory ILPMP check before prescribing opioids
• E-prescribing required for controlled substances since 2023

Compliance Essentials: What Every Telepsychiatry Provider Must Do

Regardless of your state, these are non-negotiable:

1. Proper Documentation

• Full psychiatric evaluation notes for initial visits (chief complaint, history of present illness, past psychiatric history, medication trials, mental status exam, risk assessment, diagnosis, treatment plan)
• Follow-up notes documenting medication response, side effects, adherence, and ongoing clinical rationale
• Document PDMP checks in the chart

2. PDMP Compliance

• Register for and check your state’s PDMP before prescribing controlled substances
• Most states require checking before initial prescriptions; many require periodic checks (California every 4 months, others with each refill for opioids/benzos)
• Document the query in your note: ‘Reviewed [State] PDMP — no concerning patterns identified’

3. E-Prescribing

• Use DEA-compliant e-prescribing software (two-factor authentication, audit logs)
• Nearly every state now mandates electronic prescribing for controlled substances

4. Standard of Care

• Conduct thorough evaluations before prescribing — video visits for initial controlled substance prescriptions (not phone-only)
• Appropriate follow-up intervals (monthly for stimulants in many practices)
• Risk assessment and mitigation (screen for substance use history, diversion risk)
• Clear documentation of medical necessity

5. Licensing and DEA Registration

• Must be licensed in every state where patients are located during the telemedicine encounter
• Need DEA registration in each state where you prescribe controlled substances (can have multiple state DEA numbers)
• Some states (Florida, Idaho) offer special out-of-state telehealth registrations — research your target states

6. Training Requirement

• As of 2023, all DEA registrants must complete an 8-hour training on substance use disorder and appropriate prescribing before DEA renewal (one-time requirement, waived for addiction psychiatry board certification)

The Economic Reality: Why Telehealth Prescribing Rules Matter for Your Practice

Here’s what most articles won’t tell you: These regulations directly impact your income potential and practice viability.

Multi-State Licensing Is Expensive But Necessary

Want to serve patients across state lines? Each additional state license costs $500–$2,000+ in application fees, plus ongoing renewal costs every 1–3 years. Add separate DEA registrations ($888 for 3 years per state). For a solo psychiatrist, obtaining licenses in 3–4 states can cost $5,000–$10,000 upfront.

The Interstate Medical Licensure Compact helps (currently 40+ states) by streamlining the process, but you still pay fees in each state.

NP Practice Restrictions Limit Platform Flexibility

If you’re building or joining a telehealth platform, state NP restrictions create operational complexity:

• In Texas, you need MDs to prescribe any Schedule II medications
• In Florida and Pennsylvania, NPs need supervising physicians (administrative overhead, compliance risk)
• In California and Illinois, experienced NPs can work independently (simpler, more scalable)

This affects staffing models and cost structure. Platforms in restrictive states either hire more expensive psychiatrists or build physician supervision infrastructure.

Patient Acquisition Through Platforms vs. DIY Marketing

Here’s where regulation intersects with practice growth strategy. Many psychiatrists consider DIY patient acquisition — SEO, Google Ads, directory listings. Reality check on costs:

• SEO: Takes 6–12 months of consistent investment ($2,000–$5,000/month for quality work) before generating meaningful patient flow. You need content, technical optimization, and backlinks. Most solo providers lack the expertise and patience.

• Google Ads: Mental health keywords cost $15–$40+ per click. Most clicks don’t convert. A realistic cost per booked patient is $200–$400+ once you factor in click costs, campaign optimization time, and conversion rates.

• Psychology Today and Directories: Monthly subscription fees ($30–$50 per directory) plus you’re competing with hundreds of providers on the same page. Zero guarantee of patient flow. Zocdoc charges per booking ($35–$100+), and monthly costs add up fast.

When you factor in ALL costs — agency fees, ad spend, staff time to qualify leads, no-show rates from cold leads, and months of failed campaigns — DIY patient acquisition typically costs $200–$500+ per qualified patient who actually shows up.

The Platform Alternative: Guaranteed ROI

This is why platforms like Klarity Health use a pay-per-appointment model. Instead of gambling $3,000–$5,000/month on marketing with uncertain results, you pay a standard listing fee only when a pre-qualified patient books with you.

The value proposition:

• No upfront marketing spend or monthly subscriptions
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

For a psychiatrist or PMHNP starting out or scaling up, this eliminates the risk entirely. You’re paying for results (appointments), not hope (marketing campaigns that might work).

The regulatory complexity we’ve discussed makes this model even more attractive. When you join a compliant platform that handles patient acquisition, licensing verification, PDMP integration, and state-specific compliance monitoring, you’re outsourcing the headaches while focusing on clinical care.

Preparing for the 2027 Rule Changes

Assuming DEA finalizes these rules in late 2026, here’s how to position your practice:

For Psychiatrists:

• Plan to apply for the Special Telemedicine Registration in 2027 if you want to maintain pure-telehealth practice for Schedule II prescribing
• Budget for potential registration fees (unknown, but likely $100–$500 every few years)
• Expect additional reporting requirements (platforms will likely handle this, but solo practitioners should prepare for annual controlled substance reporting)
• Continue documenting thoroughly — the higher scrutiny on telehealth controlled substance prescribing means clinical justification matters more than ever

For PMHNPs:

• If in a restricted-practice state (Texas, Florida), ensure your supervising physician relationship is formalized and compliant
• If pursuing independent practice in full-practice states, complete the required hours and apply for autonomous licenses before rule changes
• Watch for whether the Special Telemedicine Registration will be available to NPs for Schedule II — the proposal doesn’t explicitly say, but it’s likely psychiatrists only initially

For All Providers:

• Join a platform that’s actively preparing for regulatory changes (compliance infrastructure, PDMP integration, state-by-state protocols)
• Consider limiting your state coverage to 2–3 key states where you’re fully licensed and familiar with rules, rather than spreading thin
• Build strong documentation habits now — thorough notes protect you if DEA or state boards audit telehealth prescribing
• Stay informed: DEA rule finalization will be published in the Federal Register with a comment period. Follow federal and state medical board updates.

FAQ: Telehealth Prescribing for Psychiatrists

Can I prescribe ADHD medications via telehealth right now?

Yes, through December 31, 2026, you can prescribe Schedule II stimulants (Adderall, Ritalin, Vyvanse) via audio-visual telehealth to new patients without a prior in-person visit, assuming you’re licensed and DEA-registered in the patient’s state and you conduct a proper evaluation. State rules vary — in Florida, document it’s for psychiatric treatment; in Texas, if you’re an NP, you can’t prescribe Schedule II at all outside hospital settings.

What happens after the DEA extension expires at the end of 2026?

The DEA plans to implement permanent telemedicine rules. If you’re a psychiatrist, you’ll likely need to obtain a Special Telemedicine Registration to continue prescribing Schedule II medications via telehealth without in-person exams. For Schedule III–V, prescribing should continue with standard protocols. Expect more formal requirements and potentially platform-level DEA registration.

Do I need an in-person visit before prescribing benzodiazepines via telehealth?

Under current federal rules (through end of 2026), no in-person visit is required. Benzodiazepines are Schedule IV, covered under the temporary telehealth flexibilities. State laws don’t generally add extra in-person requirements specifically for benzos, but check your state PDMP before prescribing and ensure your evaluation is thorough (anxiety disorders, substance use screening, risk assessment).

Can psychiatric nurse practitioners prescribe controlled substances via telehealth?

It depends on the state. In full-practice states (New York, California for experienced NPs, Illinois with FPA), yes — PMHNPs can prescribe controlled substances including Schedule II via telehealth just like psychiatrists. In restricted states (Texas, Florida, Pennsylvania), NPs face limitations: Texas NPs can’t prescribe Schedule II for outpatient psychiatric care; Florida NPs need physician supervision; Pennsylvania NPs need collaborative agreements and have quantity limits on Schedule II prescriptions.

Which states allow psychiatrists to prescribe via telehealth without restrictions?

California, New York, Illinois, and Pennsylvania allow telehealth prescribing without state-level restrictions beyond following standard of care and PDMP requirements. Texas allows it but limits NPs. Florida allows it with the psychiatric disorder exception for Schedule II. All states require licensure and DEA registration in the state where the patient is located.

Do I need to check the PDMP every time I prescribe a controlled substance via telehealth?

Depends on state law. California requires checking before initial Schedule II–IV prescriptions and every 4 months thereafter. New York requires checking before every Schedule II–IV prescription. Texas requires checking before opioids, benzos, barbiturates, or carisoprodol. Best practice: Check before initial prescriptions and periodically during ongoing treatment (monthly for stimulants, every 3–6 months for stable benzo prescriptions). Document the check in your chart.

Can I use audio-only (phone) for telehealth prescribing of controlled substances?

Generally no, except for specific exceptions. The DEA’s current allowance technically requires audio-visual (video) encounters to meet the ‘telemedicine’ definition under Ryan Haight Act exceptions. Audio-only is explicitly permitted for buprenorphine OUD treatment under the proposed rules. For other controlled substances, use video for initial prescriptions. Some states (California, New York) permit audio-only for mental health follow-ups, but it’s not advisable for controlled substance prescribing — video provides better clinical assessment and documentation.

What’s the difference between practicing via a platform like Klarity and building my own telehealth practice?

Solo practice gives you complete autonomy but requires: obtaining multiple state licenses ($5,000–$10,000+ upfront), marketing investment ($2,000–$5,000/month for 6–12 months before results), building telehealth infrastructure (EHR, video platform, e-prescribing, PDMP integration), managing billing and insurance credentialing, and handling compliance monitoring across states. Total cost to acquire each patient: $200–$500+ when you factor in all expenses and time.

Joining a platform like Klarity: pay-per-appointment model (listing fee only when patients book), pre-qualified patient flow, built-in telehealth/EHR/e-prescribing infrastructure, compliance support for state-specific rules, insurance credentialing handled, no upfront marketing spend. You trade some per-appointment revenue for eliminating acquisition risk and administrative burden. For most providers, especially those scaling or starting out, it’s the economically rational choice.

Next Steps: Start Prescribing via Telehealth Compliantly (and Profitably)

The regulatory landscape is complex, but the opportunity is clear: telehealth expands your reach, improves work-life balance, and can significantly increase your income — if you navigate the rules correctly.

Here’s your action plan:

Immediate (Next 30 Days):

1. Verify you’re properly licensed and DEA-registered in every state where you currently see telehealth patients
2. Register for your state PDMP if you haven’t already, and integrate PDMP checks into your workflow
3. Confirm your e-prescribing system is DEA-compliant and you’re using it for all controlled substances
4. Review your documentation standards — are your telehealth notes as thorough as in-person visits?
5. If you completed the 8-hour DEA training requirement, confirm it’s on file; if not, complete it before your next DEA renewal

Near-Term (Next 90 Days):

1. If you want to expand to new states, research their specific telehealth and prescribing rules using this guide
2. Apply for additional state licenses in target markets (prioritize states in the Interstate Medical Licensure Compact if you’re a physician)
3. If you’re considering DIY marketing, calculate realistic patient acquisition costs including all-in expenses — compare to platform models
4. Ensure you have appropriate malpractice coverage for telehealth in all states where you practice

Strategic (Next 6–12 Months):

1. Watch for DEA final rule publication (likely late 2026) and prepare to apply for Special Telemedicine Registration
2. If you’re a PMHNP in a transition state (California, Illinois), complete requirements for full practice authority
3. Evaluate whether to build your own practice or join an established telehealth platform — factor in time, risk, compliance overhead, and patient acquisition economics
4. Consider specializing in high-demand telepsychiatry niches (ADHD, anxiety disorders, OUD treatment) where regulatory pathways are clearest

If you’re ready to skip the headaches and start seeing qualified patients immediately, explore joining Klarity Health’s provider network. We handle patient acquisition, state-by-state compliance, licensing verification, PDMP integration, and billing — so you can focus on clinical care while building a sustainable, profitable telehealth practice.

The regulatory framework is actually more favorable now than it’s been since before COVID, with clear federal guidance and state-specific pathways. The question isn’t whether telepsychiatry is viable — it’s whether you’ll position yourself to take advantage of the opportunity before permanent rules create new barriers to entry in 2027.

References

1. U.S. Department of Health and Human Services. (January 2, 2026). ‘HHS and DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through December 31, 2026.’ Retrieved from https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (January 16, 2025). ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Care While Establishing New Patient Protections.’ Retrieved from https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Statutes §456.47. (2025 Edition). ‘Use of Telehealth to Provide Services.’ Retrieved from http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Akerman LLP. (March 2023). ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ Retrieved from https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Texas Medical Board. (Updated 2024). ‘Prescriptive Authority and Supervision FAQs.’ Retrieved from https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

Additional sources: SAMHSA MAT Act guidance, Tebra state-by-state NP practice authority analysis (updated December 2025), JD Supra legal analysis of state telehealth prescribing rules (February 2023), California Medical Board Newsletter Vol. 169 (2024), state statutes for Pennsylvania (49 Pa. Code §21.285a) and Illinois (225 ILCS 65), New York State Office of Professions telepractice guidance (2022).

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices